[
  {
    "ts": null,
    "headline": "Healthcare: Why the sector underperformed in 2024",
    "summary": "The healthcare sector (XLV) faced significant challenges in the markets throughout 2024, becoming the worst-performing S&P 500 (^GSPC) sector of the year. Yahoo Finance Senior Health Reporter Anjalee Khemlani analyzes the key market themes that influenced the sector this year and examines investor sentiment heading into 2025 — with a detailed look at leading stocks across pharmaceutical, biotechnology, and other healthcare segments. To watch more expert insights and analysis on the latest market action, check out more Catalysts here. This post was written by Angel Smith",
    "url": "https://finnhub.io/api/news?id=c3da17b70c9a620e3f7353d5ef8a3740e69c98057f073b548babe5271da4bc9f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735228380,
      "headline": "Healthcare: Why the sector underperformed in 2024",
      "id": 132165564,
      "image": "https://s.yimg.com/ny/api/res/1.2/YSQFR5cif60nexLksofS7A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzU-/https://s.yimg.com/os/creatr-uploaded-images/2024-12/8a65d2c0-c39f-11ef-b399-ee353d1aafce",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The healthcare sector (XLV) faced significant challenges in the markets throughout 2024, becoming the worst-performing S&P 500 (^GSPC) sector of the year. Yahoo Finance Senior Health Reporter Anjalee Khemlani analyzes the key market themes that influenced the sector this year and examines investor sentiment heading into 2025 — with a detailed look at leading stocks across pharmaceutical, biotechnology, and other healthcare segments. To watch more expert insights and analysis on the latest market action, check out more Catalysts here. This post was written by Angel Smith",
      "url": "https://finnhub.io/api/news?id=c3da17b70c9a620e3f7353d5ef8a3740e69c98057f073b548babe5271da4bc9f"
    }
  },
  {
    "ts": null,
    "headline": "Better Buy: Eli Lilly vs. Novo Nordisk. The Answer Is Becoming Abundantly More Clear.",
    "summary": "Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for investors.",
    "url": "https://finnhub.io/api/news?id=e5432359ee63d97430231f0c3d809c1569d578a17f346071a103783aba39189d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735226100,
      "headline": "Better Buy: Eli Lilly vs. Novo Nordisk. The Answer Is Becoming Abundantly More Clear.",
      "id": 132165565,
      "image": "https://g.foolcdn.com/editorial/images/801921/gettyimages-2025836701-2.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for investors.",
      "url": "https://finnhub.io/api/news?id=e5432359ee63d97430231f0c3d809c1569d578a17f346071a103783aba39189d"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer Says Eli Lilly and Company (LLY)’s ‘Going To Win’",
    "summary": "We recently compiled a list of the Jim Cramer Discusses 17 Stocks And Blasts Zero Day Options. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks. In his second appearance on Squawk on the Street after the Fed’s interest rate cut, Jim Cramer […]",
    "url": "https://finnhub.io/api/news?id=6ff40b058278c4e45c7a126af81d84267efe7692c02997cc033dab8b8f9d95b7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735225733,
      "headline": "Jim Cramer Says Eli Lilly and Company (LLY)’s ‘Going To Win’",
      "id": 132165566,
      "image": "https://s.yimg.com/ny/api/res/1.2/UjoPACeXPFyN.4G.yM_TTw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the Jim Cramer Discusses 17 Stocks And Blasts Zero Day Options. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks. In his second appearance on Squawk on the Street after the Fed’s interest rate cut, Jim Cramer […]",
      "url": "https://finnhub.io/api/news?id=6ff40b058278c4e45c7a126af81d84267efe7692c02997cc033dab8b8f9d95b7"
    }
  },
  {
    "ts": null,
    "headline": "Elon Musk's Weight-Loss Secret Shakes Up Pharma Giants",
    "summary": "Novo Nordisk and Eli Lilly face soaring demand--and stiff competition--as obesity drug market transforms healthcare and profits.",
    "url": "https://finnhub.io/api/news?id=5c81a3f7aac62781930daad994df73ebfa52e4a3f1a04825a6640e387c9f4c53",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735223808,
      "headline": "Elon Musk's Weight-Loss Secret Shakes Up Pharma Giants",
      "id": 132165567,
      "image": "https://media.zenfs.com/en/us.finance.gurufocus/ff347577c1c0d2cd942b9399fde6bc37",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk and Eli Lilly face soaring demand--and stiff competition--as obesity drug market transforms healthcare and profits.",
      "url": "https://finnhub.io/api/news?id=5c81a3f7aac62781930daad994df73ebfa52e4a3f1a04825a6640e387c9f4c53"
    }
  },
  {
    "ts": null,
    "headline": "Down 19% in 1 Day, Is Novo Nordisk Stock Still a Buy?",
    "summary": "Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk's (NYSE: NVO) stock crashed by 19% on Dec. 20, after the company reported results from a late-stage clinical trial that it framed as a success.  On Dec. 20, the bull thesis for Novo Nordisk stock took a massive hit.  In terms of its financial performance, Novo Nordisk's bread and butter are its therapies for type 2 diabetes (Ozempic) and obesity (Wegovy); both are the same molecule, semaglutide, which works by targeting a cellular receptor called GLP-1.",
    "url": "https://finnhub.io/api/news?id=1c05fe8d7d4ee07a321063e083574d5a1dd2d808639df0b65316002c94e8fbf4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735218000,
      "headline": "Down 19% in 1 Day, Is Novo Nordisk Stock Still a Buy?",
      "id": 132165568,
      "image": "https://g.foolcdn.com/editorial/images/802000/concerned-investor-with-two-people-in-background.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk's (NYSE: NVO) stock crashed by 19% on Dec. 20, after the company reported results from a late-stage clinical trial that it framed as a success.  On Dec. 20, the bull thesis for Novo Nordisk stock took a massive hit.  In terms of its financial performance, Novo Nordisk's bread and butter are its therapies for type 2 diabetes (Ozempic) and obesity (Wegovy); both are the same molecule, semaglutide, which works by targeting a cellular receptor called GLP-1.",
      "url": "https://finnhub.io/api/news?id=1c05fe8d7d4ee07a321063e083574d5a1dd2d808639df0b65316002c94e8fbf4"
    }
  },
  {
    "ts": null,
    "headline": "JGRO: Losing Steam Compared To Its Peers",
    "summary": "JGRO's performance was promising in its first 20 months, but it has lagged passive large-cap growth ETFs for six months. Read why JGRO ETF is a Hold.",
    "url": "https://finnhub.io/api/news?id=2f6e89fae79deea794936c2ac7d63ab4f3bc65c77a832ce731932580fd5d7833",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735173949,
      "headline": "JGRO: Losing Steam Compared To Its Peers",
      "id": 132161438,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1022048344/image_1022048344.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "JGRO's performance was promising in its first 20 months, but it has lagged passive large-cap growth ETFs for six months. Read why JGRO ETF is a Hold.",
      "url": "https://finnhub.io/api/news?id=2f6e89fae79deea794936c2ac7d63ab4f3bc65c77a832ce731932580fd5d7833"
    }
  }
]